Status:
RECRUITING
Brain Mechanisms of Social Perception in Parkinson's Disease
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Social Perception in Parkinson's Disease
Eligibility:
All Genders
30-75 years
Phase:
NA
Brief Summary
Social cognition is a complex process that enables humans to interpret social information and behave appropriately in a social environment. Social cognition can be impaired in Parkinson's disease pati...
Eligibility Criteria
Inclusion
- Male or female between 30 and 75 years of age
- Freely-given informed consent to participate to this study (written form)
- Affiliated with a social security system or equivalent;
- Person diagnosed with Parkinson's disease according to MDS-UPDRS criteria for at least 3 years and receiving dopaminergic treatment (e.g. : LEVODOPA, CARBIDOPA, BENZERASIDE, ENTACAPONE, MODOPAR, SINEMET, STALEVO, PRAMIPEXOLE, SIFROL, ROPINIROLE, REQUIP ; ROTIGOTINE, NEUPRO, PIRIBEDIL, TRIVASTAL, RASAGILINE, AZILECT, CONTAM, AMANTADINE, MANTADIX, APOMORPHINE, APOKINON, DOPACEPTIN, FOSLEVODOPA, FOSCARBIDOPA, SCYOVA) (for patients only)
- Effective contraception for women of childbearing age or post-menopausal women (only for patients and healthy volunteers in stage 2 "imaging")
- Requiring dopa testing as part of routine care (only for patients in stage 2 "imaging")
- No disabling cognitive impairment (MOCA score ≥ 26)
- No diagnosis of chronic disease associated with disability (only for healthy volunteers)
Exclusion
- Contraindication to MRI (only for patients and healthy volunteers in step 2 "imaging"):
- Wearing a pacemaker not approved for 3 Tesla MRI
- Presence of intracerebral ferromagnetic or magnetizable material
- Presence of intraocular ferromagnetic or magnetizable foreign bodies
- Presence of non-removable ferro-magnetic or magnetizable foreign bodies in the cephalic region
- Claustrophobia
- History of head trauma with loss of consciousness lasting more than 30 min (only for patients and healthy volunteers in step 2 "imaging")
- Participant not agreeing to be informed in the event of incidental discovery of an abnormality on MRI (only for patients and healthy volunteers in stage 2 "imaging")
- Tremor or disabling dyskinesias preventing MRI (only for patients in stage 2)
- Having exceeded the annual amount of compensation allowed for participation in research protocols (only for healthy volunteers)
- Pregnant, parturient or breast-feeding women
- Persons deprived of liberty by judicial or administrative decision
- Persons under psychiatric care
- Persons admitted to a health or social institution for purposes other than research
- Adults under legal protection (guardianship, curatorship)
- Participants in other intervention research involving a period of exclusion still in progress at the time of pre-inclusion.
Key Trial Info
Start Date :
July 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT06884722
Start Date
July 15 2025
End Date
April 1 2027
Last Update
July 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de neurologie - troubles du mouvement et pathologies neuromusculaires, Hôpital neurologique Pierre Wertheimer/GHE
Bron, France, 69677